Opendata, web and dolomites


Accellta Market Study

Total Cost €


EC-Contrib. €






 Accellta project word cloud

Explore the words cloud of the Accellta project. It provides you a very rough idea of what is the project "Accellta" about.

succeeded    quantities    suspension    market    companies    personalised    plan    grade    mass    medicine    industrial    human    granted    drug    infrastructure    pioneering    acknowledged    leader    newly    quality    license    offers    customers    intellectual    organizing    cardiomyocytes    property    patents    exceptional    hold    affordable    despite    technologies    sme    1998    meeting    lines    hpsc    animal    therapies    proper    team    solutions    company    promise    differentiated    advancing    reagents    provider    ip    pharmaceutical    centre    culturing    discoveries    demands    utmost    premium    regenerative    establishment    huge    databases    emerge    stem    ltd    neuronal    vision    professionally    directives    innovative    3d    clinical    cells    industry    israel    consultation    2012    dated    accellta    direction    techniques    remarkably    biomedical    expertise    technion    cell    pluripotent    hpscs    manner    national    protected    free    services    screening   

Project "Accellta" data sheet

The following table provides information about the project.


Organization address
address: MALAT BUILDING - 3rd floor - TECHNION CITY
city: HAIFA
postcode: 3200004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-11-01   to  2015-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACCELLTA LTD IL (HAIFA) coordinator 50˙000.00


 Project objective

Human pluripotent stem cells (hPSCs) and hPSCs-derived differentiated cells, such as cardiomyocytes and neuronal cells, are rapidly advancing discoveries in drug screening and development processes and hold much promise for personalised regenerative medicine. The affordable mass production of industrial-grade high quality hPSCs will enable meeting the research and clinical demands of the rapidly growing stem cell market. Accellta Ltd. offers a range of innovative solutions for culturing mass quantities of premium quality stem cells in a cost-effective manner. These solutions are the result of research dated since 1998 at the Stem Cell Centre at the Technion – Israel Institute of Technology. As a newly developed SME, this company has exceptional expertise in innovative hPSC culturing solutions, including growing stem cells in 3D suspension, with unique, animal-free reagents. These technologies are protected by numerous pioneering, granted and acknowledged patents and since its establishment in 2012. This SME already succeeded to license its IP to multi-national cell research companies. Accellta's future vision is to become a leading provider of premium quality differentiated cell lines and services to customers, which include pharmaceutical and biomedical companies. Despite the huge market potential, proper industry and market research plan is essential and organizing a professionally conducted study, using proper consultation and market research databases, is of the utmost importance. Understanding the market's direction and demands would provide the directives in which the company can proceed and find success. Accellta has the know-how, intellectual property, team and infrastructure required to emerge as a leader in this field. The company's remarkably unique techniques in pluripotent stem cell culturing would provide high quality hPSCs-derived differentiated cells will advance drug development and regenerative therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACCELLTA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ACCELLTA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More